Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in other cancers
- New trial
Other cancers
Phase 1/2 olaparib intensifies sequential high-dose chemotherapy and autologous stem-cell rescue in relapsed germ cell tumors
This MD Anderson Phase 1/2 study adds olaparib, a PARP1/2 inhibitor developed by AstraZeneca and Merck, to a sequential high-dose chemotherapy program for relapsed or refractory germ cell tumors. The first treatment…
NCT07850973 Exploratory - Trial result
Other cancers
Preop SBRT (27–30Gy/3fx or 18–24Gy/1fx) before fixation shows 6.5% wound-complication rate in impending metastatic fractures
Preoperative SBRT is an ablative, highly conformal RT technique delivered to gross tumor (rather than a large postoperative bed), here given immediately before orthopedic stabilization to potentially improve local…
NCT05038124 - Trial result
Other cancers
Durvalumab (PD-L1) + platinum/pemetrexed: biomarker signals (BAP1/DDR, LOH) emerge despite DREAM3R OS miss in 1L pleural mesothelioma
Durvalumab is an anti–PD-L1 monoclonal antibody combined here with first-line platinum/pemetrexed chemotherapy in unresectable pleural mesothelioma (DREAM3R, randomized Phase 3; NCT04334759) that stopped early for…
NCT04334759 - Trial result
Other cancers
Selinexor (XPO1) Yields 13.6-mo mPFS in Thymoma, 7.8-mo in Thymic Carcinoma (Phase II)
Selinexor, an oral exportin-1 (XPO1/CRM1) inhibitor, was tested in two coordinated single-arm Phase II trials (US/EU) in pretreated advanced thymic epithelial tumors (n=31; median 2 prior lines). Dosed twice weekly…
- New trial
Other cancers
Phase II cemiplimab PD-1 inhibitor trial in incurable NUT carcinoma
This Phase II open-label trial by Northwestern University evaluates cemiplimab—a PD-1 directed monoclonal antibody—in patients with metastatic or unresectable NUT carcinoma lacking standard treatment. Participants…
NCT07050186 Exploratory - New trial
Other cancers
Phase II Ivonescimab: PD-1/VEGF-targeted bispecific antibody in thymic carcinoma.
This trial examines ivonescimab monotherapy in previously treated thymic carcinoma patients with IV infusions every three weeks. Patients undergo CT scans and biospecimen collection to assess treatment effects.…
NCT06980077 - Trial result
Other cancers
Precision Strikes: KRAS-G12D, RET & TRK Therapies Post Record ORRs and ctDNA Proves the Earliest Truth-Teller
Targeted drugs stole the show: KRAS-G12D inhibitors shrank pancreatic tumors in >50% of patients, RET and NTRK blockers logged 40-70% response rates across rare fusions, and HER2-selective TKIs hit 70% in mutant lung…
- New trial
Other cancers
Frontier Pipeline: DLL3 Trispecifics, PSMA Radioligands, B7-H3 ADCs—and a First Look at EPR-Imaging PET
Among 25 fresh studies, several stand out: - XB628 (NKG2A / PD-L1 bispecific) opens the door for NK-cell activation in advanced solid tumors. - Ifinatamab deruxtecan vs docetaxel could make B7-H3 ADCs the next line…
- New trial
Other cancers
Indiana University Trials Maintenance Zanzalintinib with Oral Etoposide in Relapsed Metastatic GCT
This open-label phase I/II study evaluates the safety and optimal dosing of zanzalintinib, a c-Met/VEGFR inhibitor, in combination with oral etoposide following high-dose chemotherapy and PBSCT in patients with…
NCT06937866
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.